Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-01-02
2007-01-02
Whisenant, Ethan (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024300
Reexamination Certificate
active
09820531
ABSTRACT:
Microarray technology allows the multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate, which is useful in the gathering of gene signatures defining specific biological states. An approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element. Primers specific for the regulatory genes are selected, based on minimum cross-reactivity with other genes, using known gene data banks. PCR products of selected regions of known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with the regulatable genes and control genes, referred to as “amplicons” or “gene cDNA fragments” of between about 450 and 1000 nucleotide bases in length, are obtained from a total RNA pool. These amplicons are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as a regulatory gene-specific microarray that is hybridized with sample. Sample will typically be the mRNA obtained from cells associated with a particular state (examples include age or exposure to conditions such as outspace, low gravity), disease (such as cancer or an infection), or disorder (such as a genetic defect or trauma). The transcriptionally regulated profile of regulatory gene-related genes specific to a given cultured cell sample is then determined using a software based analysis of the amount of hybridization which is detected. This information is useful in determining drug targets, markers associated with the disease state (either the presence or absence, or the extent of the disease), or the response of the disease state to drugs or other treatments.
REFERENCES:
patent: 5474796 (1995-12-01), Brennan
patent: 5605662 (1997-02-01), Heller et al.
patent: 6013437 (2000-01-01), Luria et al.
patent: 6028189 (2000-02-01), Blanchard
patent: 6136541 (2000-10-01), Gulati
patent: 6329140 (2001-12-01), Lockhart et al.
patent: 6524800 (2003-02-01), Lockhart et al.
patent: 2005/0054597 (2005-03-01), Furusawa
patent: WO9525116 (1995-09-01), None
patent: WO9535505 (1995-12-01), None
DeRisi et al., Nature Genetics 14 (4): 457-460 (Dec. 1996).
Heller et al., PNAS 94 : 2150-2155 (Mar. 1977).
Lockhart et al., Nature 405 :827-836 (Jun. 15, 2000).
Schena et al., PNAS 93 : 10,614-10,619 (1996).
Alberts et al. “Molecular Biology of the Cell”, 3rdEdition. Published by Garland Publishing, Inc. (1994) pp. 223-226.
Bowtell, “Options available—from start to finish—for obtaining expression data by microarray,”Nat Genet21(1 Suppl):25-32 (1999).
Ramsay, “DNA chips: state-of-the art,” Nat Biotechnol 16(1):40-44 (1998).
Wang, et al., “Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome,”Science280(5366):1077-1082 (1998).
Stites & Harbison PLLC
University of Louisville Research Foundation
Whisenant Ethan
LandOfFree
Microarrays to screen regulatory genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microarrays to screen regulatory genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microarrays to screen regulatory genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798919